Letters, Testimony & Comments

BIO joined with the American Pharmacists Association (APhA), Association of State and Territorial Health Officials (ASTHO), Immunization...
February 25 2014
On November 15, 2013, BIO submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding their Federally Qualified...
December 19 2013
Therapeutic biologics are an opportunity to address unmet patient needs, drive innovation, and assist China's transformation into a...
July 10 2013
Countries across the globe are realizing the significant impact rare diseases have on their populations, and are responding by putting...
June 7 2013
Dear Speaker Boehner and Minority Leader Pelosi: On behalf of the Biotechnology Industry Organization (BIO), I am writing with our...
December 18 2012
  Dear Chairmen Harkin, Upton and Pitts, Ranking Members Enzi and Waxman, Senators Burr and Casey, and Rep. Rogers:   On...
November 16 2012
  The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the Institute of Medicine’s (IOM...
June 15 2012
  The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the Institute of Medicine’s (IOM...
June 15 2012
  The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid...
May 17 2012
Re: Draft 2013 Call Letter Dear Mr. Blum and Mr. Spitalnic: The Biotechnology Industry Organization (BIO) appreciates this...
March 2 2012
Re: Request for Comments Regarding Enhancements to the Part C and Part D Plan Ratings The Biotechnology Industry Organization (BIO)...
January 20 2012
  Re:  Group Health Plans and Health Insurance Issuers Relating to Coverage of Preventive Services under the Patient...
September 30 2011
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the core set of health quality measures for the...
August 9 2011
  BIO fully supports the creation of an infectious disease standard by the Occupational Safety and Health Administration (OSHA) to...
July 29 2011
The Honorable Michael J. Rogers 133 Cannon HOB U.S. House of Representatives Washington, DC 20515 Dear Representative Rogers: On...
July 25 2011
BIO agrees with CMS that the proposed influenza vaccination standard will help increase vaccination coverage among patients, thereby...
July 5 2011
TESTIMONY OF PHYLLIS ARTHUR, SENIOR DIRECTOR FOR VACCINES, IMMUNOTHERAPEUTICS AND DIAGNOSTICS POLICY, BIOTECHNOLOGY INDUSTRY...
May 17 2011
Testimony of Phyllis Arthur, Senior Director for Vacines, Immunotherapeutics and Diagnostoics Policy Senate HELP Committee Good...
May 11 2011
BIO Comments – Adult Immunization: Complex challenges and recommendations for improvement – A report of the Adult...
April 25 2011
Hearing Testimony Phyllis Arthur Senior Director for Vaccines, Immunotherapeutics and Diagnostics Policy at the Biotechnology...
April 13 2011
Statement Opposing S.B. 2276 The Biotechnology Industry Organization (BIO) respectfully submits the following statement in opposition...
March 23 2011
HHS-OS-2010-002: Request for Information Regarding Value-based Insurance Design in Connection with Preventive Care Benefits The...
March 1 2011
Comments to the International Trade Administration: Vaccine production and additional planning for future possible pandemic influenza...
October 1 2010
Re: Interim Final Rules for Group Health Plans and Health Insurance Issuers Relating to Coverage of Preventive Services under the Patient...
September 17 2010
BIO agrees that prioritizing the select agents into stratified tiers based on an assessment of relative risk would be appropriate. We...
August 30 2010
BIO supports the draft Biennial Implementation Plan’s goal to rapidly develop and adopt countermeasures that mitigate health...
August 25 2010
Optimizing the Security of Biological Select Agents and Toxins in The United States
July 2 2010
BIO urges that funds directed for pandemic influenza and the BioShield Special Reserve Fund not be rescinded so that they are available...
June 24 2010
The Biotechnology Industry Organization (BIO) appreciates the opportunity to provide comments to the Department of Health and Human...
July 13 2007
Dear Ms. English: We commend the National Vaccine Advisory Committee (NVAC) for addresssing the challenges of adolescent immunization....
May 7 2007
Dear Dr. Coller, The Biotechnology Industry Organization (BIO) appreciates the opportunity yo provide comments to the Department of...
October 6 2006
Statement of Peter Young, President and CEO of AlphaVax, Inc. on Behalf of BIO, the Biotechnology Industry Organization Presented...
April 6 2006
HEARING ON PROJECT BIOSHIELD II OCTOBER 6, 2004 This statement is submitted by the Biotechnology Industry Organization (BIO), an...
October 6 2004
Background: On February 3, 2003, President Bush unveiled the details of Project BioShield, a comprehensive effort by the federal...
July 24 2004
The Honorable Judd Gregg Chairman Committee on Health, Education, Labor and Pensions United States Senate Washington...
May 24 2004
J. Leighton Read, M.D. General Partner, Alloy Ventures Palo Alto, CA Testifying On Behalf Of The Biotechnology Industry Organization...
March 27 2003
The Honorable Tom Daschle 509 Hart Senate Office Building Washington DC 20510 Dear Senator Daschle: The Senate will very soon be...
November 18 2002
Carl B. Feldbaum, BIO President Since its inception in the 1970's, the biotechnology industry's mission has been to improve and...
November 6 2002
Letter to Senator Ron Wyden (May 15, 2002).
May 15 2002
BIO supports S. 1764, the Robert Stevens, Thomas Morris Jr., Joseph Curseen, Kathy Nguyen, Ottilie Lundgren, and Lisa Raines Biological and...
March 3 2002
Testimony of Dr. Una S. Ryan President and CEO, AVANT Immunotherapeutics, Inc. Before the Subcommittee on Science, Technology, and...
February 5 2002
TESTIMONY OF STEPHEN G. SUDOVAR President and CEO EluSys Therapeutics, Inc. 10 Bloomfield Ave. Pine Brook, NJ 07058 973-808-0222 (...
October 23 2001
TESTIMONY U.S. House of Representatives Committee on Government Reform Subcommittee on National Security, Veterans Affairs, and...
October 23 2001
Assuring Vaccination of Children and Adolescents without Financial Barriers A Report of the National Vaccine Advisory Committee I....
Promoting Health and Preventing Disease: Childhood and Adult Vaccine Updates and Recommendations  
Draft Strategic National Vaccine Plan, 11/26/08 Preface: Letter from the Assistant Secretary for Health Given the importance of...
We are experiencing an unparalleled period of advancement and innovation in the life sciences globally that continues to transform our...
Time and again in our Nation's history, Americans have risen to meet -and to shape- moments of transition. This must be one of those...
March 7 2014
On March 7, 2014, BIO submitted comments to the U.S. Office of Personnel Management (OPM) regarding OPM’s February 4, 2014 Multi-State Plan (MSP) Program Call Letter. BIO’s comments address the critical nature of the Affordable Care Act’s immunization coverage standard.
February 25 2014
BIO joined with the American Pharmacists Association (APhA), Association of State and Territorial Health Officials (ASTHO), Immunization Action Coalition (IAC), Merck, and the National Association of County and City Health Officials (NACCHO) to submit comments to the Centers for Medicare and Medicaid Services (CMS) regarding the February 4, 2014 Draft Letter to Issuers in the Federally-facilitated Marketplaces. 
December 19 2013
BIO submitted comments on the Centers for Medicare and Medicaid Services' (CMS’s) Federally Qualified Health Center (FQHC) Prospective Payment System (PPS) proposed rule, specifically as it relates to vaccine coverage for Medicare beneficiaries and reimbursement for vaccines under Medicare Part B.
July 10 2013
Therapeutic biologics are an opportunity to address unmet patient needs, drive innovation, and assist China's transformation into a knowledge-intensive economy.
June 7 2013
BIO applauds the government of Brazil for taking steps towards developing regulatory requirements to ensure patients suffering from rare diseases have access to treatment.   
June 20 2013
BIO applauds Sens. Max Baucus (D-MT) and Orrin Hatch (R-UT) and Reps. Jim Gerlach (R-PA) and Richard Neal (D-MA) on the passage of H.R. 475 to update the existing excise tax to cover the newest seasonal influenza vaccines.
May 24 2013
Rx Response elevates to Alert status to address potential impact from Moore tornado on supply chain.
April 22 2013
Peer-reviewed article in Vaccine offers actions for bringing vaccines to 90% of the world.
March 5 2013
On March 4, 2013, the U.S. House of Representatives passed PAHPRA by a vote of 370-28.
January 25 2013
Bill will accelerate R&D to help support nation’s preparedness against chemical, biological, radiological and nuclear threats.